Skip to main content

Prediabetic State

6
Pipeline Programs
15
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%
+ 10 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
1
Dapagliflozin 10mgPhase 41 trial
DapagliflozinPhase 2Small Molecule1 trial
Active Trials
NCT07624305Not Yet Recruiting2,800Est. Jul 2030
NCT03721874Completed16Est. Jun 2021
Medica Corp
Medica CorpMA - Bedford
1 program
1
Vanadyl sulfatePhase 31 trial
Active Trials
NCT00561132Completed14Est. Nov 2004
Sandoz
SandozAustria - Kundl
1 program
1
vildagliptinPhase 3Small Molecule1 trial
Active Trials
NCT00237250Completed171Est. Jul 2006
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
DapagliflozinPhase 2Small Molecule
Bayer
BayerLEVERKUSEN, Germany
1 program
1
DapagliflozinPhase 2Small Molecule1 trial
Active Trials
NCT02695810Completed120Est. Jan 2019
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
CookingMattersN/A1 trial
PresessionsN/A1 trial
Active Trials
NCT03527641Completed20Est. Apr 2019
NCT04022499Completed483Est. Aug 2024
Labcorp
LabcorpBURLINGTON, NC
1 program
Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetesN/A1 trial
Active Trials
NCT06195566Completed77Est. Sep 2025
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Financial IncentivesN/A1 trial
Active Trials
NCT02422420Completed1,500Est. Sep 2016
Shield Therapeutics
Shield TherapeuticsMA - Wellesley
1 program
JOOL Health Mobile Phone ApplicationN/A1 trial
Active Trials
NCT03025607Completed69Est. Mar 2018
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Shared decision-making with pharmacistsN/A1 trial
Active Trials
NCT02384109Completed521Est. Jun 2019
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
Sitagliptin + Pioglitazone PLACEBON/A1 trial
Active Trials
NCT01006018Terminated3Est. Dec 2011
MSD
MSDIreland - Ballydine
1 program
Sitagliptin + Pioglitazone PLACEBON/A
Novartis
NovartisBASEL, Switzerland
1 program
vildagliptinPHASE_3Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AstraZenecaDapagliflozin 10mg
AstraZenecaDapagliflozin
Sandozvildagliptin
Medica CorpVanadyl sulfate
BayerDapagliflozin
LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes
Colorado TherapeuticsPresessions
Colorado TherapeuticsCookingMatters
Shield TherapeuticsJOOL Health Mobile Phone Application
Angeles TherapeuticsShared decision-making with pharmacists
Human BioSciencesFinancial Incentives
Sharp TherapeuticsSitagliptin + Pioglitazone PLACEBO

Clinical Trials (12)

Total enrollment: 5,794 patients across 12 trials

NCT03721874AstraZenecaDapagliflozin 10mg

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation

Start: Apr 2019Est. completion: Jun 202116 patients
Phase 4Completed
NCT07624305AstraZenecaDapagliflozin

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

Start: Sep 2026Est. completion: Jul 20302,800 patients
Phase 3Not Yet Recruiting
NCT00237250Sandozvildagliptin

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Start: Oct 2005Est. completion: Jul 2006171 patients
Phase 3Completed
NCT00561132Medica CorpVanadyl sulfate

Study of Vanadium Supplement in Patients With Impaired Glucose Tolerance

Start: Nov 2003Est. completion: Nov 200414 patients
Phase 3Completed
NCT02695810BayerDapagliflozin

The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

Start: Feb 2016Est. completion: Jan 2019120 patients
Phase 2Completed
NCT06195566LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Start: Jan 2024Est. completion: Sep 202577 patients
N/ACompleted
NCT04022499Colorado TherapeuticsPresessions

Presessions for the National Diabetes Prevention Program

Start: Aug 2019Est. completion: Aug 2024483 patients
N/ACompleted
NCT03527641Colorado TherapeuticsCookingMatters

United for Health: Type 2 Diabetes Prevention in Latino Teens

Start: May 2018Est. completion: Apr 201920 patients
N/ACompleted
NCT03025607Shield TherapeuticsJOOL Health Mobile Phone Application

A Mobile Phone-based Program for Adults With Prediabetes

Start: May 2017Est. completion: Mar 201869 patients
N/ACompleted
NCT02384109Angeles TherapeuticsShared decision-making with pharmacists

A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program

Start: Jun 2015Est. completion: Jun 2019521 patients
N/ACompleted
NCT02422420Human BioSciencesFinancial Incentives

Minnesota Medicaid Incentives to Prevent Chronic Disease

Start: Mar 2013Est. completion: Sep 20161,500 patients
N/ACompleted
NCT01006018Sharp TherapeuticsSitagliptin + Pioglitazone PLACEBO

DPP-4 Inhibition and TZD for DM Prevention

Start: Jul 2011Est. completion: Dec 20113 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.